Literature DB >> 11761440

Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor.

H Aoki1, M Mizuno, A Natsume, T Tsugawa, K Tsujimura, T Takahashi, J Yoshida.   

Abstract

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that locate in peripheral organs. It has been thought that a systemic immune response does not play a role in regression of central nervous system (CNS) tumors, because the CNS is an immunologically privileged site. However, recent advances in immunology have led to the possibility of immunotherapy using peripheral DCs against CNS tumors. Here, we investigated whether DCs pulsed with tumor extract could induce an antitumor effect against malignant glioma. Furthermore, we also investigated whether the antitumor effect become higher by pulsation with tumor extract-liposome complex, compared to pulsation with tumor extract alone. As a liposome, we used cationic small unilamellar vesicles composed of N-(alpha-trimethylammonioacetyl)-didodecyl-D-glutamate chloride (TMAG), dilauroylphosphatidylcholine (DLPC), and dioleoylphosphatidylethanolamine (DOPE) in a molar ratio of 1:2:2. After intracerebral inoculation of mouse malignant glioma GL261 cells into syngeneic C57BL/6 mice, DCs pulsed with extract from the glioma cells by sonication were administered intraperitoneally thrice weekly on days 7, 14 and 21. Tumor growth inhibition was evaluated by measuring the tumor size 1 month after the tumor inoculation. The group treated with DCs pulsed by tumor extract was inhibited in tumor progression compared with the control non-pulsed DCs group, and the group treated with DCs pulsed by tumor extract and liposomes showed substantial tumor volume reductions in all the mice. Among the mice, there were several with no visible masses in their brains. Immunohistochemical study showed that the CD8-positive cytotoxic T cells (CTLs) were strongly recognized among the almost disappearing tumor cells of pulsed DCs groups. The CTLs showed a specific antitumor activity for GL261 mouse glioma cells. These findings indicated that DCs pulsed with tumor extract and liposomes might play an important role in the activation of an immune response in malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761440     DOI: 10.1007/s002620100220

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

Review 1.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

2.  Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.

Authors:  Ryuya Yamanaka; Junpei Honma; Naoto Tsuchiya; Naoki Yajima; Tsutomu Kobayashi; Ryuichi Tanaka
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 3.  Dendritic cell vaccines for brain tumors.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 4.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 5.  Current immunotherapeutic strategies for central nervous system tumors.

Authors:  Medina C Kushen; Adam M Sonabend; Maciej S Lesniak
Journal:  Surg Oncol Clin N Am       Date:  2007-10       Impact factor: 3.495

Review 6.  An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Authors:  David A Reardon; Kai W Wucherpfennig; Gordon Freeman; Catherine J Wu; E Antonio Chiocca; Patrick Y Wen; William T Curry; Duane A Mitchell; Peter E Fecci; John H Sampson; Glenn Dranoff
Journal:  Expert Rev Vaccines       Date:  2013-06       Impact factor: 5.217

7.  Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine.

Authors:  Andrew T Parsa; John I Miller; Arnold E Eggers; Alfred T Ogden; Richard C Anderson; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

8.  Human autologous dendritic cell-glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity.

Authors:  Andrew E Sloan; Prahlad Parajuli
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 9.  Improving vaccine efficacy against malignant glioma.

Authors:  Erik Ladomersky; Matthew Genet; Lijie Zhai; Galina Gritsina; Kristen L Lauing; Rishi R Lulla; Jason Fangusaro; Alicia Lenzen; Priya Kumthekar; Jeffrey J Raizer; David C Binder; C David James; Derek A Wainwright
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

Review 10.  Cationic Nanoparticle-Based Cancer Vaccines.

Authors:  Jeroen Heuts; Wim Jiskoot; Ferry Ossendorp; Koen van der Maaden
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.